Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with the Agency for Science, Technology and Research (A*STAR) Bioprocessing Technology Institute (BTI) and National University Health System (NUHS), have developed a groundbreaking technology capable of extracting mesenchymal stem cells (MSCs) directly from pure bone marrow – also known as bone marrow aspirate (BMA), a pivotal source of MSCs – without dilution.
Recent Posts
- The vital, overlooked role of body fat in shaping your health and mind
- Crispr gene-editing technology offers new hope for HIV cure but faces delivery challenges
- Vycellix Prepares for First-in-Human Study of Novel Allogeneic Cell Therapy Powered by Its Universal Cell Engineering Platform
- Scientists use stem cells to model rare genetic blindness in children
- New nanotech method loads stem cells with extra mitochondria to recharge dying cells
- The resurgence of mesenchymal stem cell therapies


